Skip to main content
. 2021 Jun 17;26(24):2100231. doi: 10.2807/1560-7917.ES.2021.26.24.2100231

Figure 2.

Comparison of (A) monthly and (B) quarterly enrolment to RR-TB/MDR-TB treatment, World Health Organization European Region high priority TB countries, January–June 2019 and 2020a

RR-TB/MDR-TB: rifampicin-resistant tuberculosis and/or multidrug-resistant tuberculosis, TB: tuberculosis.

a Data reported from 14 of 18 World Health Organization European Region high priority TB countries.

Figure 2